Evaluation of the Abbott LCx HIV-1 RNA quantitative, a new assay for quantitative determination of human immunodeficiency virus type 1 RNA

N. Zanchetta, G. Nardi, L. Tocalli, L. Drago, C. Bossi, F. R. Pulvirenti, C. Galli, M. R. Gismondo

Research output: Contribution to journalArticlepeer-review

Abstract

A new quantitative reverse transcription (RT)-PCR assay for human immunodeficiency virus type 1 (HIV-1) RNA (Abbott LCx HIV RNA Quantitative assay) has been compared with the Organon NucliSens assay on 521 retrospective samples obtained from HIV-1-positive patients monitored during highly active antiretroviral therapy, 79 of whom were assayed also by the Chiron Quantiplex 3.0 system and on characterized panels. The LCx system showed a moderate correlation (r = 0.795) and gave higher results than the NucliSens system on 245 of 327 concordant positive samples, with similar sensitivity. Correlation with Quantiplex system results was higher (r = 0.943). LCx reproducibility was very good; the procedure was simple, well controlled, and rapid (up to 48 results in 7 h). The HIV RNA quantitative assay on the LCx system is suitable for routine use.

Original languageEnglish
Pages (from-to)3882-3886
Number of pages5
JournalJournal of Clinical Microbiology
Volume38
Issue number10
Publication statusPublished - 2000

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Fingerprint

Dive into the research topics of 'Evaluation of the Abbott LCx HIV-1 RNA quantitative, a new assay for quantitative determination of human immunodeficiency virus type 1 RNA'. Together they form a unique fingerprint.

Cite this